Mathew Thomas

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Thomas O’Hare, William C. Shakespeare, Xiaotian Zhu et al. · Cancer Cell · 2009 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +9

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

Tianjun Zhou, Lois Commodore, Wei‐Sheng Huang et al. · Chemical Biology & Drug Design · 2010 · 284 citations

Medicine, Oncology, Pharmacology +14

Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

Victor M. Rivera, Rana Anjum, Frank Wang et al. · Cancer Research · 2010 · 27 citations

Medicine, Oncology, Pharmacology +17

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

Mathew Thomas, Wei‐Sheng Huang, David Wen et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12